Protein Degradation Leader Nurix Prepares First Clinical Trial

Company Claims Unique Protein Modulation Potential

After raising nearly $330m this year, via a financing and IPO, the company is gearing up for a first-in-human trial using its platform technology.

San Francisco, California, USA Noe Valley skyline.
Following a successful IPO, San-Francisco-based Nurix is preparing its protein degradation inhibitor for clinical trials.

San-Francisco, CA-based biotech Nurix Therapeutics, Inc. is preparing its first ever Phase I trial based on its targeted protein degradation (TPD) platform, the red-hot field in which it believes it can be a leader, with its lead product, NX-212.

TPD drug platforms harness the body’s natural cellular recycling machinery – the ubiquitin proteasome system (UPS) – to break down...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip